HLA-B54 is a candidate of response to Fluoropyrimidine plus PSK therapy in gastric cancer

• Ogoshi Kyoji

  Department of Gastroenterological Surgery, Tokai University

• Isono Kaichi

  Department of Surgery, Chiba University (Retired)

抄録

It is not well known that the correlation between HLA antigens and response to cancer therapy. To evaluate the correlation among patients' outcome, HLA antigens and therapies, we used the hierarchical clustering analysis (Ward method). We examined HLA antigens as biomarkers as well as models of gene polymorphism in 1753 gastric cancer patients followed over 25 years after treatment. Among these patients, we identified that HLA haplotypes; HLA-B54-Cw1-DQ4-DR4, might be restricting to Fluoropyrimidine drugs plus PSK therapy in gastric cancer. HLA haplotypes including HLA-B54 were candidate predictors for response to FPSK therapy in gastric cancer. HLAs will be useful biomarkers for response to therapy in Japanese patients.

収録刊行物

• Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ

  Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ 17 (2), 40-44, 2009

  日本癌病態治療研究会

キーワード

• HLA-B54
• FPSK
• gastric cancer

詳細情報

• CRID: 1390282680165596032
• NII論文ID: 130000118521
• DOI: 10.4993/acrt.17.40
• ISSN: 18805469
• ISSN: 13446835
• Web Site: http://www.jstage.jst.go.jp/article/acrt/17/2/17_2_40/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2011149567
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可